FDA
approval
· 2022-06-15
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
Summary
FDA approved a supplemental application for a Sun Pharmaceutical generic combination of buprenorphine and naloxone for treating opioid dependence.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)